Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Ribociclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ribociclib as a study intervention. Browse Ribociclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
92
Shown on this page
12
Local indexed summaries
92
Local recruiting
31
The trial list below is retrieved from the live ClinicalTrials.gov search API for Ribociclib. Results on this page are currently sorted by Recently updated.

Filter and sort this therapy

These controls apply only within Ribociclib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 1–12 of 92 matching trials for Ribociclib.
Indexed local directory records.

Top conditions

Breast Cancer 26 Metastatic Breast Cancer 15 Advanced Breast Cancer 7 HER2-negative Breast Cancer 5 Early Breast Cancer 3 Glioblastoma 3

Top sponsors

Novartis Pharmaceuticals 23 AstraZeneca 5 Hoffmann-La Roche 5 Dana-Farber Cancer Institute 3 M.D. Anderson Cancer Center 3 Pfizer 3

Top locations

Boston, Massachusetts 45 Houston, Texas 38 New York, New York 33 Nashville, Tennessee 27 Philadelphia, Pennsylvania 25 Los Angeles, California 23

Indexed official records

Open in full search
Recruiting Phase 2 Interventional

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Inavolisib, Placebo, Ribociclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Marshall, Minnesota • Aberdeen, South Dakota • Mitchell, South Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 20, 2026, 7:23 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
22
States / cities
Duarte, California • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 20, 2026, 1:10 AM EDT
Recruiting Phase 3 Interventional

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767
View directory record Official record
Conditions
Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Letrozole, Letrozole-matching placebo, Palazestrant, Palazestrant matching-placebo, Ribociclib
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
28
States / cities
Hot Springs, Arkansas • Beverly Hills, California • Santa Barbara, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 20, 2026, 1:10 AM EDT
Recruiting Phase 3 Interventional

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Abemaciclib, Anastrozole, Camizestrant, Exemestane, Fulvestrant, Letrozole, Palbociclib, Ribociclib, Saruparib (AZD5305)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
52
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendale, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 20, 2026, 1:10 AM EDT
Recruiting Phase 3 Interventional

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Abemaciclib, Anastrozole, Exemestane, Fulvestrant, LY4064809, Letrozole, Palbociclib, Placebo, Ribociclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
116
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 20, 2026, 11:47 PM EDT
Recruiting Phase 3 Interventional

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ansastrozole, Exemestane, Goserelin, Letrozole, Leuprolide, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
72
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 20, 2026, 10:25 AM EDT
Recruiting Phase 3 Interventional

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Palbociclib 125mg, Ribociclib, Ribociclib 600mg
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
65 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
67
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 19, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520
View directory record Official record
Conditions
ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
Interventions
AZD8421, Abemaciclib, Camizestrant, Palbociclib, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 20, 2026, 10:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759
View directory record Official record
Conditions
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions
Abemaciclib, Atezolizumab, Everolimus, Giredestrant, Inavolisib, Ipatasertib, PH FDC SC, Palbociclib, Ribociclib, Samuraciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Duarte, California • Irvine, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 18, 2026, 4:07 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
Abemaciclib, FoundationOne Liquid CDx Assay (F1LCDx), Fulvestrant, Giredestrant, LHRH Agonist, Palbociclib, Ribociclib
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
61
States / cities
Daphne, Alabama • Auburn, California • Glendale, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 20, 2026, 11:47 PM EDT
Recruiting Phase 1 Interventional

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Goserelin, Ribociclib, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Westwood, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 19, 2026, 6:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Letrozole, Ribociclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 12, 2026, 5:12 PM EDT

About this Ribociclib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Ribociclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ribociclib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Ribociclib.